Getinge announces date of 2015 Q3 report and conference call

Getinge will issue its Q3 report for 2015 on Thursday October 15th 2015 at 13:00 CET, followed by a conference call at 15:00 CET, hosted by Alex Myers, CEO, and Ulf Grunander, CFO.

We invite fund managers, analysts and the media to participate in the conference call. Please see below details to join the conference:

Swedish dial in number: +46 (0) 8 5033 6539

UK dial in number: +44 (0) 20 3427 1904

US dial in number: +1 212 444 0481

Participant passcode: 4417648

Agenda

14:45 Call in to the conference

15:00 Review of the Q3 report

15:20 Q&A

16:00 End of conference

Two hours after the end of the conference call, a recorded version of the conference can be accessed for 5 working days on the following number:

Sweden: +46 (0) 8 5051 3897

UK: +44 (0) 20 3427 0598

US: +1 347 366 9565

Code: 4417648

During the telephone conference a presentation will be held. To access the presentation, please use this link:

http://www.livemeeting.com/cc/premconfeurope/join?id=4417648&role=attend&pw=pw4273

Alternatively enter the Live Meeting site and log into your meeting using the Meeting ID and Password below:

Live Meeting: https://www.livemeeting.com/cc/premconfeurope/

Your Name: (Enter your name)

Web Meeting ID: 4417648

Web Meeting Password: pw4273

For more information, please contact:

Kornelia Rasmussen, Head of Group Communications

Phone: +46 (0)10 335 5810

E-mail: kornelia.rasmussen@getinge.com

Getinge Group is a global leading medical technology company that operates in the areas of surgery, intensive care, infection control, care ergonomics and wound care. Getinge Group has nearly 16,000 employees in over 40 countries and generates sales of almost SEK 27 billion (2014). The Group is divided into three business areas: Medical Systems, Extended Care and Infection Control and operates under the brands of Maquet, ArjoHuntleigh and Getinge.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

Tags: